{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:02Z","timestamp":1787016902834,"version":"build-2736575974"},"reference-count":19,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1136\/bjophthalmol-2015-307136","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T21:29:05Z","timestamp":1444944545000},"page":"802-807","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study)"],"prefix":"10.1136","volume":"100","author":[{"given":"Ling Zhi","family":"Heng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Crosby-Nwaobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubin","family":"Saihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Karampelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3713","authenticated-orcid":false,"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G","family":"Hykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,10,15]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2015-307136-1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307136-2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-4","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-5","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307136-7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000320071","article-title":"Macular edema. General pathophysiology","volume":"47","author":"Augustin","year":"2010","journal-title":"Dev Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307136-8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307136-9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","article-title":"Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema","volume":"127","author":"Beck","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307136-10","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-11","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","article-title":"Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema","volume":"120","author":"Callanan","year":"2013","journal-title":"Ophthalmology,"},{"key":"key-10.1136\/bjophthalmol-2015-307136-12","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/eye.2013.287","article-title":"Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1)","volume":"28","author":"Mathew","year":"2014","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2015-307136-14","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A Randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-15","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Elman","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-16","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","article-title":"A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-307136-18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-307136-19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"30","author":"Ip","year":"2012","journal-title":"Arch Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2015-307136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:51:03Z","timestamp":1601095863000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2015-307136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,15]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,20]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1136\/bjophthalmol-2015-307136"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307136","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,15]]}}}